<DOC>
	<DOCNO>NCT02687490</DOCNO>
	<brief_summary>Abraxane patient visceral metastasis dominant metastatic breast cancer</brief_summary>
	<brief_title>Abraxane Patients With Visceral Metastases Dominant Metastatic Breast Cancer</brief_title>
	<detailed_description>A Prospective , Single-center , Open-Label , Phase II Study Abraxane patient visceral metastasis dominant metastatic breast cancer</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Histologically confirm metastatic breast cancer ; 2 . Radiologically histologically confirm visceral dominant metastasis ; 3 . Patients expect acquire benefit chemotherapy : ER and/or PR positive patient develop resistance prior endocrine therapy ; HER2+ patient experience disease progression prior target therapy suitable subsequent target therapy ; mTNBC patient relapse platinum therapy ; 4 . At least one measurable disease accord response evaluation criterion solid tumor ( RECIST 1.1 ) ; 5 . Patients receive paclitaxol metastatic set proven effective prior paclitaxol base regimen disease progress least 3 month last administration paclitaxol ; receive paclitaxel neoadjuvant/adjuvant therapy enrol disease relapse least 6 month completion neoadjuvant/adjuvant chemotherapy . Patients receive docetaxol limitation enrollment ; 6 . Eastern Cooperative Oncology Group performance ( ECOG ) status 01 ; 7 . All patient enrol required adequate hematologic , hepatic , renal function ; 8 . Life expectancy longer 12 week ; 9 . No medical history serious cardiovascular , hepatic , respiratory renal disease ; 10 . Informed consent ; 11 . Patients good compliance . 1 . Pregnant , lactate woman woman childbearing potential , unwilling use adequate contraceptive protection process study ; 2 . Patients expect acquire benefit endocrine target therapy ; 3 . Radiotherapy axial bone within 4 week enrollment lack recovery prior radiotherapy ; 4 . Treatment experimental drug within 4 week enrollment ; 5 . Patients symptomatic central nervous system metastasis permit , except stable asymptomatic brain metastasis complete cranial irradiation , least one measurable lesion outside brain . Radiotherapy complete within 4 week prior enrollment ; 6 . Other active malignancy ( include hematologic malignancy ) malignancy within last 5 year , except cure nonmelanoma skin cancer cervical intraepithelial neoplasia ; 7 . Patients history symptomatic cardiovascular , hepatic , respiratory , renal , hematological , endocrinal , neurological psychiatric disease ; 8 . Uncontrolled serious infection .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>